![Jean-Paul Laurin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jean-Paul Laurin
Corporate Officer/Principal chez ViRexx Medical Corp.
Postes actifs de Jean-Paul Laurin
Sociétés | Poste | Début | Fin |
---|---|---|---|
ViRexx Medical Corp.
![]() ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Corporate Officer/Principal | - | - |
Historique de carrière de Jean-Paul Laurin
Statistiques
Internationale
Canada | 2 |
Opérationnelle
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
ViRexx Medical Corp.
![]() ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Health Technology |
- Bourse
- Insiders
- Jean-Paul Laurin
- Expérience